Preferred Label : alogliptin;

MeSH note : structure in first source;

CISMeF synonym : SYR 322; nesina;

MeSH synonym : 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile;

MeSH hyponym : SYR322; SYR-322;

Is substance : O;

UNII : JHC049LO86;

InChIKey : ZSBOMTDTBDDKMP-OAHLLOKOSA-N;

Details


Main resources

You can consult :


http://www.has-sante.fr/portail/jcms/c_1774100/fr/vipdomet
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
drug combinations
metformin
hypoglycemic agents
Alogliptin Benzoate
metformin and alogliptin
alogliptin
dipeptidyl-peptidase iv inhibitors
incretins
adult
diabetes mellitus, type 2
treatment outcome
insurance, health, reimbursement
drug therapy, combination
piperidines
uracil
uracil

---
http://www.has-sante.fr/portail/jcms/c_1774095/fr/vipidia
2014
false
false
false
France
French
evaluation of the transparency committee
alogliptin
Alogliptin Benzoate
administration, oral
insurance, health, reimbursement
alogliptin
hypoglycemic agents
incretins
dipeptidyl-peptidase iv inhibitors
drug therapy, combination
diabetes mellitus, type 2
adult
treatment outcome
Product containing alogliptin (medicinal product)
Product containing precisely alogliptin benzoate 6.25 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 12.5 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 25 milligram/1 each conventional release oral tablet (clinical drug)
piperidines
uracil
uracil

---
Summary Basis of Decision (SBD) for Nesina
Alogliptin (as alogliptin benzoate), 6.25 mg, 12.5 mg, and 25 mg, tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00232
2014
false
Canada
French
English
alogliptin
alogliptin
drug approval
canada
administration, oral
tablets
hypoglycemic agents
hypoglycemic agents
diabetes mellitus, type 2
drug therapy, combination
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
drug interactions
treatment outcome
alogliptin
drug information
piperidines
piperidines
uracil
Product containing precisely alogliptin benzoate 6.25 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 12.5 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 25 milligram/1 each conventional release oral tablet (clinical drug)

---
https://www.ema.europa.eu/medicines/human/EPAR/Vipdomet
2013
United Kingdom
French
English
alogliptin
metformin
drug combinations
metformin
hypoglycemic agents
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
alogliptin
metformin and alogliptin
drug approval
europe
treatment outcome
adult
diabetes mellitus, type 2
drug therapy, combination
administration, oral
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
summary of product characteristics
package leaflet
syndication feed
piperidines
piperidines
uracil

---
https://www.ema.europa.eu/medicines/human/EPAR/Vipidia
2013
false
United Kingdom
English
French
Product containing alogliptin (medicinal product)
Product containing precisely alogliptin benzoate 12.5 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 6.25 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely alogliptin benzoate 25 milligram/1 each conventional release oral tablet (clinical drug)
alogliptin
alogliptin
drug approval
europe
treatment outcome
alogliptin
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
diabetes mellitus, type 2
drug therapy, combination
adult
administration, oral
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
piperidines
piperidines
uracil

---
https://www.ema.europa.eu/medicines/human/EPAR/Incresync
2013
United Kingdom
French
English
alogliptin
drug combinations
alogliptin
pioglitazone and alogliptin
drug approval
europe
treatment outcome
adult
drug therapy, combination
diabetes mellitus, type 2
hypoglycemic agents
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
administration, oral
product surveillance, postmarketing
continuity of patient care
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
thiazolidinediones
thiazolidinediones
piperidines
piperidines
uracil
Pioglitazone
Pioglitazone

---
Nous contacter.
27/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.